Nitazoxanide CR is under clinical development by Romark Laboratories LC and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Nitazoxanide CR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nitazoxanide CR overview
Nitazoxanide is under development for the treatment of coronavirus disease 2019 (COVID-19). The drug candidate is an oral controlled release formulated as capsule, tablet and powder as controlled release formulation. It is a small molecule 5-nitrothiazole compound with antiparasitic, antibacterial and antiviral activity.
It was also under development for the treatment of chronic hepatitis B and respiratory syncytial virus (RSV) infections, influenza A and B infections, enterovirus and rhinovirus infections.
Romark Laboratories LC overview
Romark Laboratories LC (Romark Laboratories) is a pharmaceutical company that discovers, develops and commercializes small molecules for the treatment of infectious diseases and cancers. It develops Nitazoxanide, an oral suspension and tablets used for the treatment of intestinal parasitic infections. Its pipeline product include NT-300, which is used in COVID-19 clinical trials. Romark Laboratories’ pipeline products are used in the therapeutic areas of anti-infective, antiviral, influenza and RSV. The company operates through its manufacturing facility located in Belgium and Puerto Rico. Romark Laboratories is headquartered in Tampa, Florida, the US
For a complete picture of Nitazoxanide CR’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
